Major deals

Vaxart has purchased equipment and sublet KindredBio's manufacturing facilities in Burlingame, California. The company will use them to manufacture materials for Vaxart's COVID-19 vaccine tablets. Vaxart plans to begin operating the facility in Q1 2022.